Should I buy or sell Syros Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYRS shares. View SYRS analyst ratings or view top-rated stocks .

What is Syros Pharmaceuticals' stock price target for 2024?

2 Wall Street analysts have issued twelve-month price objectives for Syros Pharmaceuticals' stock. Their SYRS share price targets range from $13.00 to $15.00. On average, they predict the company's share price to reach $14.33 in the next twelve months. This suggests a possible upside of 203.7% from the stock's current price. View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts .

How have SYRS shares performed in 2024?

Syros Pharmaceuticals' stock was trading at $7.79 on January 1st, 2024. Since then, SYRS stock has decreased by 39.4% and is now trading at $4.72. View the best growth stocks for 2024 here .

When is Syros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SYRS earnings forecast .

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings data on Friday, November, 5th. The company reported ($4.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.40) by $0.30. The business earned $5.70 million during the quarter, compared to the consensus estimate of $5.10 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 227.91% and a negative net margin of 1,656.34%. During the same quarter last year, the business earned ($4.30) EPS.

When did Syros Pharmaceuticals' stock split?

Shares of Syros Pharmaceuticals reverse split on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com . Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP) , Sangamo Therapeutics (SGMO) , Advanced Micro Devices (AMD) , CRISPR Therapeutics (CRSP) , ImmunoGen (IMGN) , VBI Vaccines (VBIV) , Amarin (AMRN) , Amicus Therapeutics (FOLD) , Nektar Therapeutics (NKTR) and Pfizer (PFE) .

When did Syros Pharmaceuticals IPO?

Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SYRS

Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free SYRS Stock Alerts

$4.72

-0.39 (-7.63%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.72
▼
$5.06
50-Day Range: $4.50
▼
$7.75
52-Week Range: $2.09
▼
$8.17

Volume: 119,221 shs
Average Volume: 261,391 shs
Market Capitalization: $126.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.33

Get Syros Pharmaceuticals alerts:

Syros Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 203.7% Upside
$14.33 Price Target
Short Interest: Bearish
9.89% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: -0.09
Based on 3 Articles This Week
Insider Trading: Selling Shares
$747 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.78) to ($3.30) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.71 out of 5 stars

Medical Sector

171st out of 918 stocks

Pharmaceutical Preparations Industry

62nd out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Syros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Syros Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.89% of the float of Syros Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Syros Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.
Change versus previous month
Short interest in Syros Pharmaceuticals has recently increased by 4.60%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Syros Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Syros Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Syros Pharmaceuticals has received a 64.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.
Environmental Sustainability
The Environmental Impact score for Syros Pharmaceuticals is -0.88.

1.1

News and Social Media Coverage

News Sentiment
Syros Pharmaceuticals has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Syros Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for SYRS on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Syros Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $747.00 in company stock.
Percentage Held by Insiders
10.45% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
91.47% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Syros Pharmaceuticals are expected to grow in the coming year, from ($3.78) to ($3.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Syros Pharmaceuticals is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Syros Pharmaceuticals is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Syros Pharmaceuticals has a P/B Ratio of 5.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Syros Pharmaceuticals Stock (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

SYRS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SYRS Stock News Headlines

April 18, 2024 | americanbankingnews.com

Syros Pharmaceuticals (NASDAQ:SYRS) Downgraded to Sell at StockNews.com

April 17, 2024 | americanbankingnews.com

Syros Pharmaceuticals (NASDAQ:SYRS) Stock Passes Below 50-Day Moving Average of $6.38

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 10, 2024 | marketwatch.com

Syros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for Tamibarotene

April 9, 2024 | msn.com

Syros jumps on FDA fast track tag for leukemia drug

April 9, 2024 | markets.businessinsider.com

Fast Track Designation For Syros' Tamibarotene To Treat Acute Myeloid Leukemia

April 9, 2024 | businesswire.com

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

April 2, 2024 | businesswire.com

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 29, 2024 | investing.com

Earnings call: Syros Pharmaceuticals strong Q4 and full year financials

March 29, 2024 | seekingalpha.com

Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcript

March 28, 2024 | finance.yahoo.com

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript

March 28, 2024 | markets.businessinsider.com

Syros Pharmaceuticals: Buy Rating on Strong Financials and High Potential of Tamibarotene Trials

March 28, 2024 | finance.yahoo.com

Syros Pharmaceuticals Full Year 2023 Earnings: Misses Expectations

March 27, 2024 | markets.businessinsider.com

Syros Pharmaceuticals earnings preview: what Wall Street is expecting

March 27, 2024 | investorplace.com

SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Syros Pharmaceuticals Amidst Promising Clinical Trial Developments

March 27, 2024 | businesswire.com

Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

March 25, 2024 | finance.yahoo.com

Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial

March 20, 2024 | businesswire.com

Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024

March 16, 2024 | finance.yahoo.com

SYRS Apr 2024 10.000 call

March 11, 2024 | msn.com

FibroGen appoints Deyaa Adib as Chief Medical Officer

February 28, 2024 | finance.yahoo.com

SYRS Jul 2024 2.500 call

February 27, 2024 | finance.yahoo.com

Investors in Syros Pharmaceuticals (NASDAQ:SYRS) have seen respectable returns of 99% over the past year

February 27, 2024 | finance.yahoo.com

Syros to Participate in TD Cowen 44th Annual Health Care Conference

February 27, 2024 | businesswire.com

Syros to Participate in TD Cowen 44th Annual Health Care Conference

February 23, 2024 | finance.yahoo.com

Syros Pharmaceuticals, Inc. (SYRS)

See More Headlines

Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/05/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SYRS
CUSIP: N/A
CIK: 1556263
Web: www.syros.com
Phone: (617) 744-1340
Fax: N/A
Employees: 68
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.33
High Stock Price Target: $15.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +203.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-164,570,000.00
Net Margins: -1,656.34%
Pretax Margin: -1,656.34%
Return on Equity: -227.91%
Return on Assets: -75.60%

Debt

Debt-to-Equity Ratio: 2.07
Current Ratio: 3.95
Quick Ratio: 3.95

Sales & Book Value

Annual Sales: $9.94 million
Price / Sales: 12.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.79 per share
Price / Book: 5.97

Miscellaneous

Outstanding Shares: 26,730,000
Free Float: 23,935,000
Market Cap: $126.17 million
Optionable: Optionable
Beta: 1.74

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Richard A. Young Ph.D. (Age 70)
Scientific Founder, Member of Scientific Advisory Board & Director
Comp: $108.37k
Dr. David A. Roth M.D. (Age 61)
Chief Medical Officer
Comp: $679.52k
Mr. Conley Chee (Age 54)
CEO, President & Director
Dr. James E. Bradner M.D. (Age 52)
Founder
Dr. Nathanael S. Gray Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Jason Haas (Age 56)
Chief Financial Officer
Comp: $457.22k
Ms. Karen Hunady M.S.
Director of Corporate Communications & Investor Relations
Mr. Gerald E. Quirk Esq. (Age 56)
J.D., Chief Legal Officer & Head of Business Development
Comp: $127.07k
Ms. Lisa Roberts
Vice President of Human Resources
Ms. Kristin Stephens (Age 51)
Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SYRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings or view top-rated stocks.
What is Syros Pharmaceuticals' stock price target for 2024?: 2 Wall Street analysts have issued twelve-month price objectives for Syros Pharmaceuticals' stock. Their SYRS share price targets range from $13.00 to $15.00. On average, they predict the company's share price to reach $14.33 in the next twelve months. This suggests a possible upside of 203.7% from the stock's current price.
View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts.
How have SYRS shares performed in 2024?: Syros Pharmaceuticals' stock was trading at $7.79 on January 1st, 2024. Since then, SYRS stock has decreased by 39.4% and is now trading at $4.72.
View the best growth stocks for 2024 here.
When is Syros Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SYRS earnings forecast.
How were Syros Pharmaceuticals' earnings last quarter?: Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings data on Friday, November, 5th. The company reported ($4.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.40) by $0.30. The business earned $5.70 million during the quarter, compared to the consensus estimate of $5.10 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 227.91% and a negative net margin of 1,656.34%. During the same quarter last year, the business earned ($4.30) EPS.
When did Syros Pharmaceuticals' stock split?: Shares of Syros Pharmaceuticals reverse split on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?: 3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Syros Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).
When did Syros Pharmaceuticals IPO?: Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
How do I buy shares of Syros Pharmaceuticals?: Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SYRS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial